Fosun Pharma Subsidiary Gains Approval for Schizophrenia Drug Trial

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.

Shanghai Fosun Pharmaceutical’s subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., has received approval from the National Medical Products Administration to conduct a clinical trial for CMC-2310 Oral Soluble Film, a treatment for schizophrenia in adults and pediatric patients aged 13 and older. This approval marks a significant step in the company’s R&D efforts, having invested RMB 7.25 million in the drug’s development. The drug, with the same active ingredient, was previously approved for marketing in China in 2024, indicating the company’s ongoing commitment to expanding its pharmaceutical offerings.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and marketing of pharmaceutical products, with a particular emphasis on innovative drug development and healthcare services.

YTD Price Performance: 10.20%

Average Trading Volume: 5,648

Technical Sentiment Signal: Hold

Current Market Cap: $8.52B

See more insights into 2196 stock on TipRanks’ Stock Analysis page.